Tricor patent settlement allows Teva generic in 2011 at the earliest
02 December 2009
Sue Sutter
Please Login to read the full article.
02 December 2009
Sue Sutter
sue.sutter@informa.com
Abbott Laboratories has settled US patent litigation with Teva Pharmaceutical Industries, allowing the generics firm to market a competitor to its cholesterol-lowering Tricor (fenofibrate) 145mg tablets in 2011 at the earliest.
The agreement gives Teva a licence for intellectual property...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Cubist value jumps $250 million on Cubicin patent settlement with Teva
- Mylan suit pushes FDA to decide immediately on Ranbaxy ANDA for generic Lipitor
- Medicines Co shares rise 12% on US settlement with Teva on Angiomax patents
- Pfizer's 'non obvious' Viagra patents good until 2019 to fend off Teva in US
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
